A Multi-center Phase I/II Trial of Memory T Cell Donor Lymphocyte Infusions After Transplantation of CliniMACS® TCRα/β and CD19 Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Cell Transplantation
The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.
∙ Adult and pediatric patients with hematological malignancies in complete remission (CR), partial remission (PR) or with stable disease
• Acute myeloid leukemia (AML):
‣ Patients with high-risk AML in first complete remission (CR1)
⁃ Patients with relapsed or primary therapy-refractory AML
• Acute lymphoid leukemia (ALL):
‣ Patients with high-risk ALL in CR1
⁃ Patients with relapsed or primary refractory ALL
• Hodgkin's disease: Patients with relapsed or primary refractory Hodgkin's disease
• Non-Hodgkin's lymphoma: Patients with relapsed or primary refractory Non- Hodgkin's lymphoma
• Myelodysplastic Syndrome (MDS)/ Myeloproliferative Syndrome (MPS):
• °Patients with refractory MDS/MPS
• Multiple myeloma (MM): Patients with relapsed or refractory multiple myeloma